ID   I2BPL_HUMAN             Reviewed;         796 AA.
AC   Q9H1B7; Q8NDQ2; Q96JG2; Q9H3I7;
DT   29-AUG-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   07-APR-2021, entry version 161.
DE   RecName: Full=Probable E3 ubiquitin-protein ligase IRF2BPL {ECO:0000305};
DE            EC=2.3.2.27 {ECO:0000305|PubMed:29374064};
DE   AltName: Full=Enhanced at puberty protein 1;
DE   AltName: Full=Interferon regulatory factor 2-binding protein-like;
GN   Name=IRF2BPL; Synonyms=C14orf4, EAP1, KIAA1865; ORFNames=My039;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], TISSUE SPECIFICITY, TRIPLET REPEAT
RP   EXPANSION, AND POLYMORPHISM.
RX   PubMed=11095982; DOI=10.1006/bbrc.2000.3883;
RA   Rampazzo A., Pivotto F., Occhi G., Tiso N., Bortoluzzi S., Rowen L.,
RA   Hood L., Nava A., Danieli G.A.;
RT   "Characterization of C14orf4, a novel intronless human gene containing a
RT   polyglutamine repeat, mapped to the ARVD1 critical region.";
RL   Biochem. Biophys. Res. Commun. 278:766-774(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H.,
RA   Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T.,
RA   Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B.,
RA   Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D.,
RA   Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R.,
RA   Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S.,
RA   Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C.,
RA   Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S.,
RA   Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C.,
RA   Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P.,
RA   Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J.,
RA   Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F.,
RA   Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F.,
RA   Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=11347906; DOI=10.1093/dnares/8.2.85;
RA   Nagase T., Nakayama M., Nakajima D., Kikuno R., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XX. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 8:85-95(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 332-796.
RC   TISSUE=Fetal brain;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 694-796.
RC   TISSUE=Fetal brain;
RA   Mao Y.M., Xie Y., Zheng Z.H.;
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-662, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [8]
RP   MUTAGENESIS OF CYS-715.
RX   PubMed=17627301; DOI=10.1172/jci31752;
RA   Heger S., Mastronardi C., Dissen G.A., Lomniczi A., Cabrera R., Roth C.L.,
RA   Jung H., Galimi F., Sippell W., Ojeda S.R.;
RT   "Enhanced at puberty 1 (EAP1) is a new transcriptional regulator of the
RT   female neuroendocrine reproductive axis.";
RL   J. Clin. Invest. 117:2145-2154(2007).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-662, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-547; SER-657; SER-658;
RP   SER-659 AND SER-662, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-547; SER-657; SER-659 AND
RP   SER-662, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-547; SER-659 AND SER-662, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-69; SER-519; SER-547;
RP   SER-639; SER-657; SER-659 AND SER-662, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-215; SER-519; SER-547;
RP   SER-657; SER-659 AND SER-662, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-79, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [19]
RP   FUNCTION, INVOLVEMENT IN NEDAMSS, VARIANTS NEDAMSS 126-GLN--PRO-796 DEL;
RP   127-GLN--PRO-796 DEL; 172-GLU--PRO-796 DEL; 188-ARG--PRO-796 DEL; VAL-195;
RP   ARG-372 AND ASN-418, AND CHARACTERIZATION OF VARIANTS NEDAMSS
RP   127-GLN--PRO-796 DEL; 172-GLU--PRO-796 DEL; 188-ARG--PRO-796 DEL; ARG-372
RP   AND ASN-418.
RX   PubMed=30057031; DOI=10.1016/j.ajhg.2018.07.006;
RG   Program for Undiagnosed Diseases (UD-PrOZA);
RG   Undiagnosed Diseases Network;
RA   Marcogliese P.C., Shashi V., Spillmann R.C., Stong N., Rosenfeld J.A.,
RA   Koenig M.K., Martinez-Agosto J.A., Herzog M., Chen A.H., Dickson P.I.,
RA   Lin H.J., Vera M.U., Salamon N., Graham J.M. Jr., Ortiz D., Infante E.,
RA   Steyaert W., Dermaut B., Poppe B., Chung H.L., Zuo Z., Lee P.T., Kanca O.,
RA   Xia F., Yang Y., Smith E.C., Jasien J., Kansagra S., Spiridigliozzi G.,
RA   El-Dairi M., Lark R., Riley K., Koeberl D.D., Golden-Grant K., Yamamoto S.,
RA   Wangler M.F., Mirzaa G., Hemelsoet D., Lee B., Nelson S.F., Goldstein D.B.,
RA   Bellen H.J., Pena L.D.M.;
RT   "IRF2BPL Is Associated with Neurological Phenotypes.";
RL   Am. J. Hum. Genet. 103:245-260(2018).
RN   [20]
RP   FUNCTION, AND INTERACTION WITH CTNNB1.
RX   PubMed=29374064; DOI=10.1158/0008-5472.can-17-2403;
RA   Higashimori A., Dong Y., Zhang Y., Kang W., Nakatsu G., Ng S.S.M.,
RA   Arakawa T., Sung J.J.Y., Chan F.K.L., Yu J.;
RT   "Forkhead Box F2 Suppresses Gastric Cancer through a Novel FOXF2-IRF2BPL-
RT   beta-Catenin Signaling Axis.";
RL   Cancer Res. 78:1643-1656(2018).
RN   [21]
RP   INVOLVEMENT IN NEDAMSS.
RX   PubMed=30166628; DOI=10.1038/s41436-018-0143-0;
RA   Tran Mau-Them F., Guibaud L., Duplomb L., Keren B., Lindstrom K., Marey I.,
RA   Mochel F., van den Boogaard M.J., Oegema R., Nava C., Masurel A., Jouan T.,
RA   Jansen F.E., Au M., Chen A.H., Cho M., Duffourd Y., Lozier E.,
RA   Konovalov F., Sharkov A., Korostelev S., Urteaga B., Dickson P., Vera M.,
RA   Martinez-Agosto J.A., Begemann A., Zweier M., Schmitt-Mechelke T.,
RA   Rauch A., Philippe C., van Gassen K., Nelson S., Graham J.M. Jr.,
RA   Friedman J., Faivre L., Lin H.J., Thauvin-Robinet C., Vitobello A.;
RT   "De novo truncating variants in the intronless IRF2BPL are responsible for
RT   developmental epileptic encephalopathy.";
RL   Genet. Med. 21:1008-1014(2019).
RN   [22]
RP   STRUCTURE BY NMR OF 705-786.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the ZF-C3HC4 domain of human KIAA1865.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [23]
RP   3D-STRUCTURE MODELING OF 708-771, AND RING FINGER.
RX   PubMed=17334524; DOI=10.1590/s0100-879x2006005000075;
RA   Scior T., Luna F., Koch W., Sanchez-Ruiz J.F.;
RT   "In silico analysis identifies a C3HC4-RING finger domain of a putative E3
RT   ubiquitin-protein ligase located at the C-terminus of a polyglutamine-
RT   containing protein.";
RL   Braz. J. Med. Biol. Res. 40:293-299(2007).
CC   -!- FUNCTION: Probable E3 ubiquitin protein ligase involved in the
CC       proteasome-mediated ubiquitin-dependent degradation of target proteins
CC       (PubMed:29374064). Through the degradation of CTNNB1, functions
CC       downstream of FOXF2 to negatively regulate the Wnt signaling pathway
CC       (PubMed:29374064). Probably plays a role in the development of the
CC       central nervous system and in neuronal maintenance (Probable). Also
CC       acts as a transcriptional regulator of genes controlling female
CC       reproductive function. May play a role in gene transcription by
CC       transactivating GNRH1 promoter and repressing PENK promoter (By
CC       similarity). {ECO:0000250|UniProtKB:Q5EIC4,
CC       ECO:0000269|PubMed:29374064, ECO:0000305|PubMed:17334524,
CC       ECO:0000305|PubMed:29374064, ECO:0000305|PubMed:30057031}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27; Evidence={ECO:0000305|PubMed:29374064};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000305|PubMed:29374064}.
CC   -!- SUBUNIT: Interacts with CTNNB1. {ECO:0000269|PubMed:29374064}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:Q5EIC4}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in the heart, moderately in
CC       skeletal muscle and pancreas, and weakly in brain, kidney, liver,
CC       testis, thyroid gland and lymphocytes. {ECO:0000269|PubMed:11095982}.
CC   -!- POLYMORPHISM: The poly-Gln region is polymorphic; the most frequent
CC       allele contained 24 Gln. Stretches of 20-31 Gln are observed in healthy
CC       individuals. {ECO:0000269|PubMed:11095982}.
CC   -!- DISEASE: Neurodevelopmental disorder with regression, abnormal
CC       movements, loss of speech, and seizures (NEDAMSS) [MIM:618088]: An
CC       autosomal dominant disorder characterized by global developmental delay
CC       or neurodevelopmental regression, hypotonia, progressive ataxia,
CC       intellectual disability, seizures, and abnormal movements.
CC       {ECO:0000269|PubMed:30057031, ECO:0000269|PubMed:30166628}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the IRF2BP family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB47494.1; Type=Miscellaneous discrepancy; Note=Aberrant splicing.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ277365; CAC10539.1; -; Genomic_DNA.
DR   EMBL; AC007686; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AB058768; BAB47494.1; ALT_SEQ; mRNA.
DR   EMBL; AL832320; CAD38615.1; -; mRNA.
DR   EMBL; AF063597; AAG43156.1; -; mRNA.
DR   CCDS; CCDS9854.1; -.
DR   PIR; JC7555; JC7555.
DR   RefSeq; NP_078772.1; NM_024496.3.
DR   PDB; 2B9G; Model; -; A=708-771.
DR   PDB; 2CS3; NMR; -; A=705-784.
DR   PDBsum; 2B9G; -.
DR   PDBsum; 2CS3; -.
DR   SMR; Q9H1B7; -.
DR   BioGRID; 122101; 25.
DR   CORUM; Q9H1B7; -.
DR   IntAct; Q9H1B7; 7.
DR   MINT; Q9H1B7; -.
DR   STRING; 9606.ENSP00000238647; -.
DR   GlyGen; Q9H1B7; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9H1B7; -.
DR   PhosphoSitePlus; Q9H1B7; -.
DR   BioMuta; IRF2BPL; -.
DR   DMDM; 34395562; -.
DR   EPD; Q9H1B7; -.
DR   jPOST; Q9H1B7; -.
DR   MassIVE; Q9H1B7; -.
DR   MaxQB; Q9H1B7; -.
DR   PaxDb; Q9H1B7; -.
DR   PeptideAtlas; Q9H1B7; -.
DR   PRIDE; Q9H1B7; -.
DR   ProteomicsDB; 80395; -.
DR   Antibodypedia; 54435; 15 antibodies.
DR   Ensembl; ENST00000238647; ENSP00000238647; ENSG00000119669.
DR   GeneID; 64207; -.
DR   KEGG; hsa:64207; -.
DR   UCSC; uc001xsy.4; human.
DR   CTD; 64207; -.
DR   DisGeNET; 64207; -.
DR   GeneCards; IRF2BPL; -.
DR   HGNC; HGNC:14282; IRF2BPL.
DR   HPA; ENSG00000119669; Low tissue specificity.
DR   MalaCards; IRF2BPL; -.
DR   MIM; 611720; gene.
DR   MIM; 618088; phenotype.
DR   neXtProt; NX_Q9H1B7; -.
DR   OpenTargets; ENSG00000119669; -.
DR   PharmGKB; PA25516; -.
DR   VEuPathDB; HostDB:ENSG00000119669.4; -.
DR   eggNOG; KOG3579; Eukaryota.
DR   GeneTree; ENSGT00940000162596; -.
DR   HOGENOM; CLU_019307_1_0_1; -.
DR   InParanoid; Q9H1B7; -.
DR   OMA; DMLPQPH; -.
DR   OrthoDB; 1156771at2759; -.
DR   PhylomeDB; Q9H1B7; -.
DR   TreeFam; TF317075; -.
DR   PathwayCommons; Q9H1B7; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 64207; 7 hits in 1001 CRISPR screens.
DR   ChiTaRS; IRF2BPL; human.
DR   EvolutionaryTrace; Q9H1B7; -.
DR   GeneWiki; C14orf4; -.
DR   GenomeRNAi; 64207; -.
DR   Pharos; Q9H1B7; Tdark.
DR   PRO; PR:Q9H1B7; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; Q9H1B7; protein.
DR   Bgee; ENSG00000119669; Expressed in layer of synovial tissue and 223 other tissues.
DR   Genevisible; Q9H1B7; HS.
DR   GO; GO:0005615; C:extracellular space; HDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003714; F:transcription corepressor activity; IBA:GO_Central.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:UniProtKB.
DR   GO; GO:0046543; P:development of secondary female sexual characteristics; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0007399; P:nervous system development; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   InterPro; IPR022750; Interferon_reg_fac2-bd1_2_Znf.
DR   Pfam; PF11261; IRF-2BP1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Coiled coil; Disease variant; Epilepsy; Isopeptide bond;
KW   Mental retardation; Metal-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Transferase; Triplet repeat expansion; Ubl conjugation;
KW   Zinc; Zinc-finger.
FT   CHAIN           1..796
FT                   /note="Probable E3 ubiquitin-protein ligase IRF2BPL"
FT                   /id="PRO_0000056411"
FT   ZN_FING         715..762
FT                   /note="RING-type; degenerate"
FT   COILED          85..132
FT                   /evidence="ECO:0000255"
FT   COILED          335..371
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        88..102
FT                   /note="Poly-Ala"
FT   COMPBIAS        103..127
FT                   /note="Poly-Gln"
FT   COMPBIAS        153..164
FT                   /note="Poly-Ala"
FT   COMPBIAS        174..296
FT                   /note="Gly/Pro-rich"
FT   COMPBIAS        596..623
FT                   /note="Pro-rich"
FT   MOD_RES         69
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         215
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         519
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         547
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         639
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         657
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         658
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         659
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         662
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   CROSSLNK        79
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VARIANT         126..796
FT                   /note="Missing (in NEDAMSS)"
FT                   /evidence="ECO:0000269|PubMed:30057031"
FT                   /id="VAR_081415"
FT   VARIANT         127..796
FT                   /note="Missing (in NEDAMSS; loss of function)"
FT                   /evidence="ECO:0000269|PubMed:30057031"
FT                   /id="VAR_081416"
FT   VARIANT         172..796
FT                   /note="Missing (in NEDAMSS; loss of function)"
FT                   /evidence="ECO:0000269|PubMed:30057031"
FT                   /id="VAR_081417"
FT   VARIANT         188..796
FT                   /note="Missing (in NEDAMSS; loss of function)"
FT                   /evidence="ECO:0000269|PubMed:30057031"
FT                   /id="VAR_081418"
FT   VARIANT         195
FT                   /note="G -> V (in NEDAMSS; unknown pathological
FT                   significance; dbSNP:rs770422700)"
FT                   /evidence="ECO:0000269|PubMed:30057031"
FT                   /id="VAR_081419"
FT   VARIANT         372
FT                   /note="P -> R (in NEDAMSS; unknown pathological
FT                   significance; no effect on function; dbSNP:rs1555377336)"
FT                   /evidence="ECO:0000269|PubMed:30057031"
FT                   /id="VAR_081420"
FT   VARIANT         418
FT                   /note="K -> N (in NEDAMSS; loss of function;
FT                   dbSNP:rs201073695)"
FT                   /evidence="ECO:0000269|PubMed:30057031"
FT                   /id="VAR_081421"
FT   MUTAGEN         715
FT                   /note="C->A: Loss of transcription activity."
FT                   /evidence="ECO:0000269|PubMed:17627301"
FT   STRAND          716..718
FT                   /evidence="ECO:0007744|PDB:2CS3"
FT   STRAND          727..729
FT                   /evidence="ECO:0007744|PDB:2CS3"
FT   HELIX           740..751
FT                   /evidence="ECO:0007744|PDB:2CS3"
FT   STRAND          752..754
FT                   /evidence="ECO:0007744|PDB:2CS3"
FT   STRAND          767..772
FT                   /evidence="ECO:0007744|PDB:2CS3"
FT   HELIX           777..784
FT                   /evidence="ECO:0007744|PDB:2CS3"
SQ   SEQUENCE   796 AA;  82659 MW;  DCF7898F15AD6A37 CRC64;
     MSAAQVSSSR RQSCYLCDLP RMPWAMIWDF SEPVCRGCVN YEGADRIEFV IETARQLKRA
     HGCFQDGRSP GPPPPVGVKT VALSAKEAAA AAAAAAAAAA AAQQQQQQQQ QQQQQQQQQQ
     QQQQQQQLNH VDGSSKPAVL AAPSGLERYG LSAAAAAAAA AAAAVEQRSR FEYPPPPVSL
     GSSSHTARLP NGLGGPNGFP KPTPEEGPPE LNRQSPNSSS AAASVASRRG THGGLVTGLP
     NPGGGGGPQL TVPPNLLPQT LLNGPASAAV LPPPPPHALG SRGPPTPAPP GAPGGPACLG
     GTPGVSATSS SASSSTSSSV AEVGVGAGGK RPGSVSSTDQ ERELKEKQRN AEALAELSES
     LRNRAEEWAS KPKMVRDTLL TLAGCTPYEV RFKKDHSLLG RVFAFDAVSK PGMDYELKLF
     IEYPTGSGNV YSSASGVAKQ MYQDCMKDFG RGLSSGFKYL EYEKKHGSGD WRLLGDLLPE
     AVRFFKEGVP GADMLPQPYL DASCPMLPTA LVSLSRAPSA PPGTGALPPA APSGRGAAAS
     LRKRKASPEP PDSAEGALKL GEEQQRQQWM ANQSEALKLT MSAGGFAAPG HAAGGPPPPP
     PPLGPHSNRT TPPESAPQNG PSPMAALMSV ADTLGTAHSP KDGSSVHSTT ASARRNSSSP
     VSPASVPGQR RLASRNGDLN LQVAPPPPSA HPGMDQVHPQ NIPDSPMANS GPLCCTICHE
     RLEDTHFVQC PSVPSHKFCF PCSRESIKAQ GATGEVYCPS GEKCPLVGSN VPWAFMQGEI
     ATILAGDVKV KKERDP
//
